Vistagen Therapeutics Stock Market Value
| VTGN Stock | USD 2.58 0.05 1.98% |
| Symbol | VistaGen |
VistaGen Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
VistaGen Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to VistaGen Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of VistaGen Therapeutics.
| 10/24/2024 |
| 11/23/2024 |
If you would invest 0.00 in VistaGen Therapeutics on October 24, 2024 and sell it all today you would earn a total of 0.00 from holding VistaGen Therapeutics or generate 0.0% return on investment in VistaGen Therapeutics over 30 days. VistaGen Therapeutics is related to or competes with Synlogic, AC Immune, Entera Bio, Tempest Therapeutics, Quoin Pharmaceuticals, Cocrystal Pharma, and Ibio. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing vario... More
VistaGen Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure VistaGen Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess VistaGen Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.27) | |||
| Maximum Drawdown | 9.65 | |||
| Value At Risk | (3.82) | |||
| Potential Upside | 3.42 |
VistaGen Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for VistaGen Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as VistaGen Therapeutics' standard deviation. In reality, there are many statistical measures that can use VistaGen Therapeutics historical prices to predict the future VistaGen Therapeutics' volatility.| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (1.34) |
VistaGen Therapeutics Backtested Returns
VistaGen Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.23, which indicates the firm had a -0.23% return per unit of risk over the last 3 months. VistaGen Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate VistaGen Therapeutics' Coefficient Of Variation of (447.07), risk adjusted performance of (0.16), and Variance of 5.15 to confirm the risk estimate we provide. The entity has a beta of 0.39, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, VistaGen Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding VistaGen Therapeutics is expected to be smaller as well. At this point, VistaGen Therapeutics has a negative expected return of -0.54%. Please make sure to validate VistaGen Therapeutics' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if VistaGen Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.71 |
Almost perfect reverse predictability
VistaGen Therapeutics has almost perfect reverse predictability. Overlapping area represents the amount of predictability between VistaGen Therapeutics time series from 24th of October 2024 to 8th of November 2024 and 8th of November 2024 to 23rd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of VistaGen Therapeutics price movement. The serial correlation of -0.71 indicates that around 71.0% of current VistaGen Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.71 | |
| Spearman Rank Test | -0.86 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
VistaGen Therapeutics lagged returns against current returns
Autocorrelation, which is VistaGen Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting VistaGen Therapeutics' stock expected returns. We can calculate the autocorrelation of VistaGen Therapeutics returns to help us make a trade decision. For example, suppose you find that VistaGen Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
VistaGen Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If VistaGen Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if VistaGen Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in VistaGen Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
VistaGen Therapeutics Lagged Returns
When evaluating VistaGen Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of VistaGen Therapeutics stock have on its future price. VistaGen Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, VistaGen Therapeutics autocorrelation shows the relationship between VistaGen Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in VistaGen Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with VistaGen Stock
Moving against VistaGen Stock
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out VistaGen Therapeutics Correlation, VistaGen Therapeutics Volatility and VistaGen Therapeutics Alpha and Beta module to complement your research on VistaGen Therapeutics. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
VistaGen Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.